about
Therapeutic Approaches to Genetic Ion Channelopathies and Perspectives in Drug DiscoveryTaurine: the appeal of a safe amino acid for skeletal muscle disordersEffects of Nandrolone in the Counteraction of Skeletal Muscle Atrophy in a Mouse Model of Muscle Disuse: Molecular Biology and Functional EvaluationDaily treatment with SMTC1100, a novel small molecule utrophin upregulator, dramatically reduces the dystrophic symptoms in the mdx mouseSynthesis of new 2,6-prolylxylidide analogues of tocainide as stereoselective blockers of voltage-gated Na(+) channels with increased potency and improved use-dependent activity.Glial dystrophin-associated proteins, laminin and agrin, are downregulated in the brain of mdx mouse.Therapeutic screening in the mdx mouse.Different ability of clenbuterol and salbutamol to block sodium channels predicts their therapeutic use in muscle excitability disorders.Angiotensin II modulates mouse skeletal muscle resting conductance to chloride and potassium ions and calcium homeostasis via the AT1 receptor and NADPH oxidaseEffects of taurine analogues on chloride channel conductance of rat skeletal muscle fibers: a structure-activity relationship investigation.Paracrine effects of IGF-1 overexpression on the functional decline due to skeletal muscle disuse: molecular and functional evaluation in hindlimb unloaded MLC/mIgf-1 transgenic micePre-clinical trials in Duchenne dystrophy: what animal models can tell us about potential drug effectiveness.Growth hormone secretagogues modulate the electrical and contractile properties of rat skeletal muscle through a ghrelin-specific receptor.A multidisciplinary evaluation of the effectiveness of cyclosporine a in dystrophic mdx mice.Enhancing translation: guidelines for standard pre-clinical experiments in mdx miceTaurine and skeletal muscle disorders.Duchenne muscular dystrophy: focus on pharmaceutical and nutritional interventions.Towards developing standard operating procedures for pre-clinical testing in the mdx mouse model of Duchenne muscular dystrophyEnalapril treatment discloses an early role of angiotensin II in inflammation- and oxidative stress-related muscle damage in dystrophic mdx miceIncreased sodium channel use-dependent inhibition by a new potent analogue of tocainide greatly enhances in vivo antimyotonic activity.Stakeholder cooperation to overcome challenges in orphan medicine development: the example of Duchenne muscular dystrophy.An olive oil-derived antioxidant mixture ameliorates the age-related decline of skeletal muscle function.Increased hindrance on the chiral carbon atom of mexiletine enhances the block of rat skeletal muscle Na+ channels in a model of myotonia induced by ATXStructural requisites of 2-(p-chlorophenoxy)propionic acid analogues for activity on native rat skeletal muscle chloride conductance and on heterologously expressed CLC-1.Searching for novel anti-myotonic agents: pharmacophore requirement for use-dependent block of skeletal muscle sodium channels by N-benzylated cyclic derivatives of tocainide.Gene expression in mdx mouse muscle in relation to age and exercise: aberrant mechanical-metabolic coupling and implications for pre-clinical studies in Duchenne muscular dystrophy.Disuse of rat muscle in vivo reduces protein kinase C activity controlling the sarcolemma chloride conductance.Assessment of resveratrol, apocynin and taurine on mechanical-metabolic uncoupling and oxidative stress in a mouse model of duchenne muscular dystrophy: A comparison with the gold standard, α-methyl prednisolone.Combined modifications of mexiletine pharmacophores for new lead blockers of Na(v)1.4 channels.Carboxylic acids and skeletal muscle chloride channel conductance: effects on the biological activity induced by the introduction of methyl groups on the aromatic ring of chiral alpha-(4-chloro-phenoxy)alkanoic acids.Carboxylic acids and skeletal muscle chloride channel conductance: effects on the biological activity induced by the introduction of an aryloxyalkyl group alpha to the carboxylic function of 4-chloro-phenoxyacetic acid.GLPG0492, a novel selective androgen receptor modulator, improves muscle performance in the exercised-mdx mouse model of muscular dystrophy.Molecular requisites for drug binding to muscle CLC-1 and renal CLC-K channel revealed by the use of phenoxy-alkyl derivatives of 2-(p-chlorophenoxy)propionic acid.Enhanced dystrophic progression in mdx mice by exercise and beneficial effects of taurine and insulin-like growth factor-1.Inhibition of skeletal muscle sodium currents by mexiletine analogues: specific hydrophobic interactions rather than lipophilia per se account for drug therapeutic profile.Changes of chloride channel regulation in rat skeletal muscle during aging.N-aryl-2,6-dimethylbenzamides, a new generation of tocainide analogues as blockers of skeletal muscle voltage-gated sodium channels.Decrease in resting calcium and calcium entry associated with slow-to-fast transition in unloaded rat soleus muscle.Optimal requirements for high affinity and use-dependent block of skeletal muscle sodium channel by N-benzyl analogs of tocainide-like compounds.Different flecainide sensitivity of hNav1.4 channels and myotonic mutants explained by state-dependent block.
P50
Q26744730-2B447F40-A989-4A90-9D6F-A2A97E5CAE03Q26799770-696B444C-C59C-4D82-A821-51E98D3D014BQ27304606-99EC5F20-AEF4-4098-A403-A84A18689F17Q28478068-E103AD5A-8A77-493F-9A00-ED72AF7DF4F5Q31446481-42247B1B-EBA9-452B-A15F-3A0EE74F457CQ33660218-99814406-E8B5-4C28-A56D-EB2115DAD2BBQ33933848-B17274C3-B981-43FD-B48F-A9C400CCC3DBQ34180008-A3D0359D-5551-49ED-A7E9-B03C729506EFQ34295366-FF81EC34-6D8C-47CD-AFEC-986BDFAF218BQ34726549-09371B1A-CF9C-413E-A1C0-5A18B8BE195AQ34766154-05D621D3-9D33-4ABD-ACEE-D4ED406A4C9CQ34807169-19BF9ABB-4F58-456D-BC8A-C858F3528D5EQ35045389-38606805-6E58-4ECC-9A26-CA5A8B3A3801Q35083651-9E91554C-1167-4A7C-ACCE-75ABCECC46E2Q35583176-314B61F5-7490-4EE9-9350-94AD50B9BA27Q35678828-9033B3CA-5595-4155-AD72-78605A2FD639Q36669820-6F25736B-961C-4FF5-846C-C6E015CF631AQ36841572-8AFD083E-56F9-4143-8E97-43400E5604B7Q38603674-53086E9D-EC7D-4BF5-A312-1A3B97211683Q38733384-7FBE6CDA-4935-4CC6-9348-90249E277F84Q38865431-47FE0FBE-EE9E-468C-99D1-5FA96B7B12D1Q41868299-20C20ECC-7287-4183-A374-9CC1387DB86FQ41994180-4721051E-CFA3-48EF-BBF7-886A06E64769Q42019489-BD03821B-1A8E-4E56-8719-E1DB7FC9E0BBQ42080376-ECB31ED3-2187-4779-9061-94460CF88AEFQ42460420-834877BB-0455-45D7-9227-CA2E19666972Q42518795-CF3B94CA-46B3-431D-A554-EA9EFADC7692Q42699287-B1319EAB-A1DA-461D-B044-81915F3C2DDBQ42928982-4DBE5EEC-F1B1-4869-B5BD-F0E7063A387AQ43642535-24F2872E-D79B-482C-9CE2-10BD9748DBE8Q43805712-BE93B536-DF4B-4454-AD41-E27AD50505F4Q44048764-B5BB8E2F-7344-4CAD-908A-2DA389B8F26CQ44072155-5D37D39A-7C08-4DD3-8832-668EE023E921Q44255035-CAADCB6E-64F2-4653-8BB9-39E1DEA110CCQ44367477-2920E6B8-22AC-4796-B5E8-A96A1C4A508AQ44416902-C538F3AB-3F24-4E18-86DF-31F63F35FFC8Q44489520-EF349D1C-2CC6-4D4D-94DA-DAFD87C3ABA4Q44552025-58B54988-7529-4F67-84A1-DA700A30BA8BQ44590880-0FC10482-03D7-4434-AF35-49687A0D7B68Q44649200-AF8A8E09-42A6-4949-9499-368E29E93EA7
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Annamaria De Luca
@ast
Annamaria De Luca
@en
Annamaria De Luca
@es
Annamaria De Luca
@nl
type
label
Annamaria De Luca
@ast
Annamaria De Luca
@en
Annamaria De Luca
@es
Annamaria De Luca
@nl
prefLabel
Annamaria De Luca
@ast
Annamaria De Luca
@en
Annamaria De Luca
@es
Annamaria De Luca
@nl
P106
P1153
7201948236
P21
P31
P496
0000-0002-5652-7341